Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Panitumumab (Primary) ; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Criterium
- 25 Jul 2023 Planned End Date changed from 1 Mar 2023 to 1 Jan 2025.
- 25 Jul 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2024.
- 25 Jul 2023 Status changed from recruiting to active, no longer recruiting.